DSIP is a neuropeptide originally isolated from animal brain tissue that is investigated for its potential to improve sleep quality and modulate circadian rhythms. It is studied in research settings as a sleep aid and recovery agent.
Notes
DSIP research in humans remains limited and ongoing; most data come from animal studies or small clinical trials. It is not approved by the FDA as a pharmaceutical and is marketed for research purposes only. Clinical efficacy in humans is not conclusively established. This guide is for educational and harm-reduction purposes and does not constitute medical advice.
DSIP acts on central nervous system receptors and is believed to promote slow-wave (deep) sleep by modulating neurotransmitter activity and hypothalamic signaling. The exact mechanism remains incompletely characterized, but it appears to enhance sleep onset and architecture rather than simply inducing sedation.
DSIP is a 9-amino acid peptide with poor oral bioavailability; research typically uses intramuscular or subcutaneous administration. Peak levels occur within hours of injection. Being peptide-based, it is rapidly degraded by proteolytic enzymes and clears relatively quickly from circulation.
Typical Dose
Typically 100–200 mcg per dose in research settings, often administered once daily in the evening or before bed.
Frequency
Daily, typically in the evening before sleep.
Administration
Intramuscular injection or subcutaneous injection
Half-Life
~3–4 hours (estimated; limited precise data in humans)